156 related articles for article (PubMed ID: 12842427)
1. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
Bowman JE; Reese JS; Lingas KT; Gerson SL
Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
[TBL] [Abstract][Full Text] [Related]
2. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
Davis BM; Reese JS; Lingas K; Gerson SL
J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
[TBL] [Abstract][Full Text] [Related]
3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
[TBL] [Abstract][Full Text] [Related]
4. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU.
Lee K; Gerson SL; Maitra B; Koç ON
J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516
[TBL] [Abstract][Full Text] [Related]
5. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy.
Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL
Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923
[TBL] [Abstract][Full Text] [Related]
7. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.
Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL
J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757
[TBL] [Abstract][Full Text] [Related]
8. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
[TBL] [Abstract][Full Text] [Related]
10. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H
Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
[TBL] [Abstract][Full Text] [Related]
12. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
Maze R; Kurpad C; Pegg AE; Erickson LC; Williams DA
J Pharmacol Exp Ther; 1999 Sep; 290(3):1467-74. PubMed ID: 10454526
[TBL] [Abstract][Full Text] [Related]
13. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
[TBL] [Abstract][Full Text] [Related]
14. Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Fontes AM; Davis BM; Encell LP; Lingas K; Covas DT; Zago MA; Loeb LA; Pegg AE; Gerson SL
Mol Cancer Ther; 2006 Jan; 5(1):121-8. PubMed ID: 16432170
[TBL] [Abstract][Full Text] [Related]
15. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
[TBL] [Abstract][Full Text] [Related]
16. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
[TBL] [Abstract][Full Text] [Related]
17. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.
Davis BM; Koç ON; Gerson SL
Blood; 2000 May; 95(10):3078-84. PubMed ID: 10807772
[TBL] [Abstract][Full Text] [Related]
18. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
Sawai N; Zhou S; Vanin EF; Houghton P; Brent TP; Sorrentino BP
Mol Ther; 2001 Jan; 3(1):78-87. PubMed ID: 11162314
[TBL] [Abstract][Full Text] [Related]
19. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
Zielske SP; Gerson SL
Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Reese JS; Davis BM; Liu L; Gerson SL
Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
